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ABSTRACT
Several chromosomal abnormalities detected by conventional cytogenetic analysis have an adverse impact on
the outcome in myeloma patients. A wide spectrum of abnormalities involving chromosomes 1, 13, 14, and 17
has been described. We analyzed the outcome of 83 patients with clonal cytogenetic abnormalities, who
underwent high-dose therapy and autologous stem cell transplantation for multiple myeloma at our institution.
Clonal abnormalities were detected at diagnosis by conventional cytogenetic analysis in 83 patients. Patients
underwent a single autologous transplant between April 2000 and May 2005. Preparative regimen was
high-dose melphalan alone (73), or a combination of topotecan, melphalan, and cyclophosphamide (TMC 
10). The most commonly observed chromosomal abnormalities were deletion of chromosome 13 (32%),
hyperdiploidy (21%), deletion of chromosome 1p (18%), and t (11; 14) in 7% patients. Median follow-up among
surviving patients was 25.5 months. Median interval from diagnosis to autotransplant was 7.7 months (range:
2.5-52). Median progression-free survival (PFS) for the entire group was 19 months and the median overall
survival (OS) was 52 months. On univariate analysis, both PFS and OS were significantly shorter in patients
with deletion 1p (P  .001 and <.0001, respectively). Thirty-two patients whose cytogenetic abnormalities
returned to normal prior to autotransplant had longer PFS and OS than patients with persistent abnormalities
(P  .02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in
patients undergoing high-dose therapy and a single autologous transplant for myeloma.
© 2007 American Society for Blood and Marrow Transplantation
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pNTRODUCTION
Each year approximately 15,000 patients in the
nited States are diagnosed with multiple myeloma
MM) a clonal disorder of plasma cells [1]. The me-
ian survival is about 3.5 years, but it ranges from a
ew months to more than 10 years [2]. Several ran-
omized trials have shown that autologous HSCT is
ssociated with superior complete remission (CR) rates,
rolonged event-free survival (EFS), and overall survival l
066OS) [3-5]. Two other randomized trials, however, were
nable to conﬁrm the beneﬁts of autotransplants [6,7].
The presence or the absence of chromosomal ab-
ormalities has emerged as an important prognostic
actor in MM. Clonal chromosomal abnormalities can
e detected in approximately 30% of patients with
M by conventional cytogenetic studies [8,9]. This
ow yield has been attributed to a low percentage of
lasma cells in the bone marrow (BM) and low pro-
iferation rate of plasma cells as only a few analyzable
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Deletion of the Short Arm of Chromosome 1 1067ells can be obtained [10]. However, chromosomal
bnormalities are almost universal if more sensitive
olecular genetic techniques, such as interphase ﬂu-
rescent in situ hybridization (FISH) and comparative
enomic hybridization (CGH) are used [11,12].
Chromosomal abnormalities include loss or gain of
hromosomes, or chromosomal translocations [13,14].
ypodiploidy (10%-15% of chromosomal abnormali-
ies) is associated with a shorter survival [15], and, con-
ersely, hyperdiploidy (30% of chromosomal abnormal-
ties) tends to have a better prognosis [16,17]. Among
ther common abnormalities chromosome 13 deletions
50% of conventional cytogenetic abnormalities) are as-
ociated with a lower response rate and shorter survival
18-21]. Translocations involving IgH locus (14q32)
ave also been reported in a signiﬁcant number of pa-
ients (10% of conventional cytogenetic abnormalities).
f these, t (11; 14) is associated with improved or neutral
urvival [22,23], whereas t(4; 14) and t(14; 16) are asso-
iated with a shorter survival [24-26]. Deletion of short
rm of chromosome 17 (17p13) is seen in 10% of my-
loma patients and involves the p53 tumor suppressor
ene. This is associated with disease progression and
dvanced disease stage [26].
Loss of chromosome 1p (del 1p) and gain of chro-
osome 1q have been described in many cancers [27].
hese chromosomal abnormalities are frequently ob-
erved in MM [28,29]. In a recent report by Shaugh-
essy et al. [28] altered transcriptional regulation of
enes mapping to chromosome 1 contributed to dis-
ase progression and early death.
We retrospectively analyzed the frequency of var-
ous chromosomal abnormalities and their impact on
he outcome of high-dose therapy and a single auto-
ransplant in patients treated at our institution be-
ween January 2000 and November 2005.
ETHODS
atients
Between January 2000 and November 2005, 625
atients with MM underwent an autotransplant at
ur institution. We identiﬁed 162 patients (26%)
ho had cytogenetic abnormalities detected by con-
entional chromosomal analysis at the time of diag-
osis. When we narrowed down our search to pa-
ients with symptomatic myeloma according to
nternational Myeloma Working Group’s classiﬁca-
ion [30], who underwent a single autotransplant,
nd who had at least 2 abnormal metaphases by
onventional cytogenetic analysis, the number was
educed to 83. We excluded isolated deletion of the
chromosome that is considered an age-relatedhenomenon [31]. treatment
Seventy-three patients received an autotransplant
fter a preparative regimen of high-dose melphalan
200 mg/m2 i.v.). Ten patients were treated with
MC regimen: topotecan 3 mg/m2 i.v.  5 days 
elphalan 70 mg/m2 i.v.  2 days  cyclophospha-
ide 1 g/m2 i.v.  3 days [32]. All patients provided
igned institutional review board-approved informed
onsent for an autotransplant. Unmanipulated au-
ografts were infused 48 hours later. All patients re-
eived granulocyte colony-stimulating factor (G-
SF), 5 g/kg/day from day 1 until the absolute
eutrophil count (ANC) was 0.5  109/L for 2 con-
ecutive days, in accordance with our departmental
uidelines. Oral levoﬂoxacin, acyclovir, and ﬂucon-
zole were given for the duration of neutropenia.
lood products were given for hemoglobin 8 g/dL
nd platelets 20  109/L.
esponse Criteria
The European Group for Blood and Marrow
ransplantation (EBMT) response criteria was used
o deﬁne complete response (CR), partial response
PR), and relapse [33]. CR was deﬁned as the absence
f original monoclonal protein in urine and serum by
mmunoﬁxation, 5% plasma cells in marrow aspi-
ate, and no circulating plasma cells, no increase in
ize or number of lytic bony lesions, and disappear-
nce of soft tissue plasmacytomas. Progressive disease
as deﬁned as 1 of the following: (1) 25% increase
n serum or urine monoclonal protein, or plasma cells
n the bone marrow, or (2) increase in the size or
umber of lytic bony lesions.
hromosomal Analysis
Bone marrow samples were obtained at the time of
iagnosis and before an autotransplant from all the
nalyzed patients. Conventional chromosomal analy-
is was performed on the bone marrow cells by using
tandard cytogenetic techniques. Brieﬂy, after a 3- to
-day culture with interleukin-3 and interleukin-6,
-banding with Wright stain was done for all karyo-
ypes. The Chromosomal abnormalities were deﬁned
ccording to the International System for Human
ytogenetic Nomenclature (ISCN) 95 [9,34]. At least
0 metaphases, where possible, were analyzed for
ach patient. A clonal abnormality was deﬁned as 2
etaphases with the same numerical or structural ab-
ormality.
tatistical Analysis
Actuarial rates of OS and progression-free survival
PFS) were estimated by the Kaplan-Meier method.
FS and OS were deﬁned as the time from the day of
ransplant to progression or death. Prognostic factors
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M. H. Qazilbash et al.1068or survival were evaluated using Cox’s proportional
azards model for univariate analyses and multivariate
nalysis. The factors evaluated included in addition to
ytogenetic abnormalities, age, disease stage, disease
tatus at transplant, time between diagnosis and trans-
lant, lactate dehydrogenase (LDH) level, 2m, se-
um albumin level, serum creatinine level, and condi-
ioning regimen. Outcomes according to prognostic
actors were compared at 2 years after transplantation.
tatistical signiﬁcance was deﬁned at the .05 level.
nalysis was performed using STATA 7.0 (StataCorp,
001, Stata Statistical Software: Release 7.0. College
tation, TX: Stata Corporation). EFS and OS were
easured from the day of transplant.
ESULTS
atients
Table 1 outlines the basic patient characteristics of
he 83 patients reported in this retrospective analysis.
edian follow-up among surviving patients was 25.5
onths (range: 3-69). Median age was 56 (range: 34-
5) years, and the median interval from diagnosis to
utotransplant was 7.7 months (range: 2.5-53).
According to Durie-Salmon Staging System for
M [35], 44 patients (53%) had stage III disease at
iagnosis. Sixty-four patients were transplanted for
he consolidation of ﬁrst remission or for primary
efractory disease, whereas 19 patients were trans-
lanted for relapsed disease. Eleven patients (13%)
ad elevated serum creatinine above the upper limits
f normal (1.5 mg/dL).
esponse and Survival
CR were seen in 19% of patients, whereas partial
esponses (PR) were seen in 45%, with an overall
esponse rate (Cr  PR) of 64%. Median PFS for the
able 1. Patient Characteristics
Parameter Number (%)
ale 53 (63%)
edian interval diagnosis to transplant (months) 7.7 (2.5-53)
urie-Salmon Stage III 44 (53%)
SS Stage >II-III 35 (42%)
mmunoglobulin subtype 46 (55%)
ormalization of cytogenetic abnormalities at
transplant 32 (38%)
lbumin < 3.5 g/dL 25 (30%)
reatinine >1.5 mg/dL 11 (13%)
2 microglobulin > 3 mg/dL 48 (58%)
DH > normal 30 (36%)
elapsed disease at transplant 19 (23%)
reparative regimen
Melphalan (200 mg/m2) 73 (88%)
TMC (topotecan/melphalan/cyclophosphamide) 10 (12%)t
edian age (months) 56 (34-75)ntire group was 19 months and the median OS was
2 months.
hromosomal Abnormalities
The frequency of common chromosomal abnor-
alities is shown in Table 2. The most frequently
bserved abnormality was the deletion of chromo-
ome 13 that was seen in 27 of 83 (32%) patients.
ther commonly seen abnormalities were: hyperdi-
loidy in 18 (22%) patients, del 1p in 15 (18%) pa-
ients, del 17p in 12 (14%) patients, and t (11; 14) in
(7%) patients.
rognostic Factors
Del 1p emerged as the strongest negative predic-
or of outcome. In 15 patients with del 1p, the median
FS and OS were 12 and 22 months, respectively. As
hown in Figure 1A and B, these were signiﬁcantly
ower than all the other patients, who had a PFS of 26
onths and an OS that has not been reached yet (P 
001 and .0001, respectively).
In our analysis del 13 (P  .2 and .3), del 17 (P 
2 and .6), and abnormalities of chromosome 14q32
P .5 and .5) did not emerge as signiﬁcant predictors
f PFS or OS. Ten of the 15 patients with del 1p had
oncurrent del 13. There was no signiﬁcant difference
etween the PFS of these 10 patients compared to the
patients with del 1p alone (2-year PFS 20% versus
7%, P  .77). Similarly, there was no impact for
onditioning regimen, age, disease stage, 2m, or se-
um creatinine.
esolution of Chromosomal Abnormalities
efore Autotransplant
Thirty-two of the 83 patients had converted to
ormal karyotype after induction treatment and prior
o autotransplant. Only 3 of the 15 patients with del
p had achieved a normal diploid cytogenetics prior to
utotransplant. When compared to patients with per-
istent chromosomal abnormalities at autotransplant,
able 2. Common Chromosomal Abnormalities at Diagnosis
Abnormality Frequency (%)
yperdiploidy 18 (22%)
ypodiploidy 6 (7%)
el 1p 15 (18%)
el 13 27 (32%)
4q32 abnormalities 12 (14%)
el 1p  Del 13 10 (12%)
el 1p  Del 17 5 (6%)
el 1p  hypodiploidy 2 (2.5%)
el 1p  hyperdiploidy 3 (3.6%)
el 13 indicates deletion of chromosome 13; Del 1p, deletion of short
arm of chromosome 1; Del 17, deletion of chromosome 17.hese 32 patients had a signiﬁcantly better PFS (P 
.
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Deletion of the Short Arm of Chromosome 1 106902) and a trend towards superior OS (P .08) (Figure
A and B).
ISCUSSION
The adverse prognostic role of chromosomal ab-
ormalities has recently been established in MM [8].
n this analysis, we observed that del 1p was associated
ith a short PFS and OS after a single autologous
ransplant. The response rate of 64% in this analysis
as lower than our historic control (approximately
0%), perhaps because of the inclusion of a greater
umber of high-risk patients, and a signiﬁcant number
f patients (25%) with relapsed or refractory disease
36]. The PFS and OS of 12 and 22 months, respec-
ively, in these patients were signiﬁcantly lower than
igure 1. A, Kaplan-Meier estimate of progression-free survival in
urvival in patients with del 1p versus others.ur historic control, which includes comparable pa- aients without chromosomal abnormalities. In this
ontrol group of patients, we observed PFS of 24-36
onths, and a OS of 5 years [36,37].
Abnormalities of chromosome 1 are commonly
een in MM [28,29,38]. In a recent report by Shaugh-
essy et al. [28], altered transcriptional regulation of
enes mapping to chromosome 1 contributed to dis-
ase progression and early death. Short-arm abnor-
alities were usually deletional and long-arm abnor-
alities were generally associated with ampliﬁcation.
ajority of upregulated genes were mapped to 1q and
ownregulated genes mapped to 1p. In another report
y Wu et al. [39], abnormalities of chromosome 1 p
nd q were strongly associated with chromosome 13
eletion and a shorter OS. In our analysis, del 13 did
ot emerge as an independent predictor of PFS or OS,
ts with del 1p versus others. B, Kaplan-Meier estimate of overallpatienlthough it assumed statistical signiﬁcance when com-
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M. H. Qazilbash et al.1070ined with del 1p. This discrepancy can be explained
y a small number of patients and lack of FISH data;
ence, many patients with chromosome 13 abnormal-
ties might not have been detected, retrospective na-
ure of the analysis and heterogeneous patient popu-
ation.
In this report we identiﬁed the del 1p to be asso-
iated with poor outcome. Twelve of the 15 (80%) 1p
eletions were seen in the 1p13-1p22 region. No
nique gene expression consequences of deletions at
p have been identiﬁed. Previous studies have dem-
nstrated that deletion of a particular locus within the
hromosome harboring a tumor suppressor gene is
rucial in the pathogenesis of cancer. Identiﬁcation of
he speciﬁc tumor suppressor genes on chromosome 1
as been an area of growing interest and a few candi-
ate genes have emerged. Tumor suppressor gene
73, with close homology to p53, has been identiﬁed
n chromosome band 1p36.33 [40]. Del 1 p, resulting
n a loss of tumor suppressor genes seems to be the
ost probable reason for poor outcome in our pa-
ients. It will be important to delineate the minimal
igure 2. A, Kaplan-Meier estimate of progression-free surviva
bnormalities. B, Kaplan-Meier estimate of overall survival in patierea of deletion, which could harbor possible tumor suppressor genes. This area will be a focus of research
n the future to map the missing gene or genes by
ore sensitive studies like FISH or array CGH.
In our report 32 patients with baseline chromo-
omal abnormalities achieved a normal karyotype after
nduction therapy. These 32 patients had longer PFS
nd OS after an autotransplant than patients with
ersistent abnormalities. Rajkumar et al. [41] and Tri-
ot et al. [42] have also reported on the impact of
retransplant cytogenetic abnormalities on the out-
ome. Their reports, however, did not speciﬁcally
ddress the impact of resolution of cytogenetic ab-
ormalities prior to transplant on the outcome. The
onversion to normal karyotype may also be a re-
ection of lower tumor burden and fewer malignant
ells with clonal abnormalities. We feel that it is an
nteresting observation that needs to be validated in
arger studies.
Our study for the ﬁrst time established the prog-
ostic signiﬁcance of del 1p in patients undergoing
igh-dose therapy and a single autologous transplant.
his abnormality was associated with a signiﬁcantly
tients with normal cytogenetics versus persistent chromosomal
h normal cytogenetics vs. persistent chromosomal abnormalities.l in pahorter remission and survival in patients undergoing
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Deletion of the Short Arm of Chromosome 1 1071igh-dose therapy and a single autologous transplant.
e recommend that these high-risk patients should
e treated on clinical trials that include more intense
nduction, tandem autotransplants, and posttransplant
aintenance with novel agents.
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